Patent intelligence · US
US 9629932
Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof
Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof
Patent details — US 9629932
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 25, 2017
- Expiration
- Apr 20, 2037
- Applicant
- SANOCHEMIA PHARMAZEUTIKA AG
- Claims
- 6
- CPC classes
- A61K, A61K31/121, A61K36/38, A61K41/00
Quick answer
US 9629932 (Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof) is held by SANOCHEMIA PHARMAZEUTIKA AG. Status: granted. Granted Apr 25, 2017. Expires Apr 20, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SANOCHEMIA PHARMAZEUTIKA AG
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/121, A61K36/38, A61K41/00, A61K41/0057, A61K47/32
More from SANOCHEMIA PHARMAZEUTIKA AG
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12226455
Medical composition for treating cardiac wasting and cachexia
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Frequently asked questions
What is US patent 9629932?
US 9629932 (Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof) is held by SANOCHEMIA PHARMAZEUTIKA AG. Status: granted. Granted Apr 25, 2017. Expires Apr 20, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9629932?
SANOCHEMIA PHARMAZEUTIKA AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 9629932 expire?
Our index shows an expiration date of Apr 20, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.